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Chemical-Biological Reactions Common
to Teratogenesis and Mutagenesis
by Raymond D. Harbison*
Cytotoxic chemicals have in common the ability to act specifically on cells in cycle. Bacteria are more
sensitive in the exponential growth phase than when growing slowly in media. Similar observations have
been made on a variety of systems ranging from bacteria, yeast, higher plants and invertebrates to
vertebrates including primates. The embryo and fetus are highly susceptible to cytotoxic agents because
they have continuous groups ofcells in thegrowth phase. Acutely toxic doses may cause cellulardeath and
result in developmental defects or fetal death. Cytotoxic agents can be grouped as alkylating agents,
electrophilic reactants, antimetabolites, intercalating agents, amino acid antagonists, spindle poisons, and
an additional group ofchemicals which covalently bind to DNA. Thesecytotoxic groups ofchemicals may
also be mutagenic by interacting with DNA to produce changes in sequences of nucleotides resulting in
heritable defects either in a somatic cell line or in a germinal cell line. The mechanisms of chemical-
induced teratogenicity and mutagenicity are similar. This commonality is further discussed in the text.
The biological functions that make up the pro-
cesses ofreproduction and organogenesis are varied
in nature and in their susceptibility to adverse influ-
ences in the environment. A graphic display of the
developmental sequences of embryonic and fetal
growth is shown in Figure 1. The critical periods
during human development can be divided into an
embryonic period and a fetal development period,
with most organogenesis complete during the first
trimester. A relative comparison development chart
is shown in Table 1. This table sequences several
developmental stages of man, mouse, rat, hamster,
and rabbit.
The most prominent example of specific
chemical-induced alteration during a specific time
of gestational development is thalidomide.
Thalidomide was teratogenic when taken during
gestational days 34 through 50 (2). Generally, ear
anomalies were associated with intake between
days 34 and 38, arm anomalies were seen between
days 40 and 44, and aplasia of the femur or tibia
between days 44 and 48. A variety ofmalformations
of internal organs, such as intestinal atresia, im-
perforate anus, and aplasia of the gallbladder and
appendix also occurred, either associated with
skeletal defects oroccasionally alone. Ateratogenic
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response is determined by both the time ofexposure
as well as the chemical reactivity of the material.
Although it is widely known that under certain
conditions some aspects of reproduction are vul-
nerable to physical and chemical factors in the envi-
ronmcnt, for example, both the germ cells and the
early embryo may be damaged by relatively small
doses of ionizing radiation or reactive chemicals, it
is generally assumed that a placental barrier pro-
tects the embryo and or fetus against most levels of
chemical exposure. The placenta which performs
admirably in maintaining the growing embryo, does
not selectively protect the intrauterine organism
from harmful agents administered during preg-
nancy. The placental barrier has turned out to be a
sieve. Except for compounds of large molecular
weight and those with strong electronegative or
electropositive charges (heparin and most
neuromuscular blocking agents), almost all phar-
macologic substances can and do pass from the
maternal to fetal bloodstream. Generally, sub-
stances with a molecular weight of less than 600
pass the placental barrier.
Variances in placental transport of drugs and
chemicals can be demonstrated between species
and during gestation. A difference in placental
transfer of diphenylhydantoin (DPH) occurred at
different developmental periods (see Table 1). A
significantly greater DPH concentration was found
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FIGURE 1. Schematic representation ofhuman development and
sensitive periods for production ofmaldevelopment. Shaded
areas represent highly sensitive periods; clearareas represent
stages that are less sensitive to teratogens.
Table 1. Comparative gestational development.a
Man Rat Mouse Rabbit Hamster
Implantation 6hdays 8days 5 days 9days 7days
period
13 to20 27days Ildays 9days 10days 9days
somites
Endof
embryonic 12-14 14days 13 days 11 days 10days
period wk.
Endofmeta- 20wk. 17days 17days 15days 14days
morphosis
Fetal 20-34 18-22 18-20 16-32 15-16
development wk. days days days days
Parturition 36-40 21 days 19days 32days 15days
wk.
a Developmental data derived from Witshi (1) and Rugh (2).
in rat fetal tissue on gestation day 8, the period of
implantation, and day 11, the 13-20 somite stage,
than on days 14 and 17, the period offetal matura-
tion (Fig. 2). Finally, on day 21 of gestation, the
fetal DPH concentration was elevated 2.5-fold,
being at the level seen in early pregnancy. Similar
gestation dependent transport was observed in
mouse, rabbit and hamster for diphenylhydantoin.
There were no significant maternal plasma drug
level changes that would produce the observed fetal
drug level differences.
Differences of placental transfer were observed
between species (Fig. 3). The maternal rat, mouse,
hamster and rabbit were treated on gestation days
corresponding to the end ofthe embryonic period in
each species, as previously described. Mouse fetal
and placental tissues contained significantly higher
concentrations of DPH than those of any of the
RAT FETUS
800-
_ 600
z E0
0 0 -o _ °
z - 400
U 7 o
ow
--
! 200
a
+ -I- ±4
8 II 14 17 21
GESTATIONAL DAY
FIGURE 2. Concentration of DPH plus metabolites in rat fetal
tissue. Each bar represents the mean ± SE of samples from
10-13 animals killed 4 hr after IV administration of50 mg/kg
[14C] DPH (2.5 ,uCi/kg)-
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FIGURE 3. Concentration of DPH plus metabolites in placenta
and fetal tissue of rat, mouse, hamster, and rabbit compared
at the end of the embryonic period (see Table 1). Each bar
representsthe mean ± SE ofsamplesfrom5-10animals killed
4 hr after IV administration of 50 mg/kg [41C] DPH (2.5
,uCi/kg).
other species, whereas hamster fetal and placental
levels were higher than idi the rabbits and rats. Al-
though the concentration in the rabbit tissues was
higher than the rat, the difference is not significant.
These differences become even more important
when compared with the maternal plasma levels.
Mice which had the highest fetal level, and rats
which had the lowest, had essentially identical
plasma levels of DPH. Rabbits and hamsters had
plasma levels twice that of the mice, yet both had
fetal levels significantly less than that of the mice.
Environmental Health PerspectivesSimilar gestational-dependent transfer was ob-
served in human tissue (Fig. 4). Intracellular uptake
for this substrate varied with gestation. Thus pla-
cental transfer can be expected to vary during ges-
tation and between species making generalizations
and anthropomorphizing animal data difficult.
Extraplacental transfer of drugs must also be a
consideration when drugs are administered in-
traperitoneally in an experimental situation. The
contribution of extraplacental transfer is shown in
Figure 5. Uterine arteries were ligated, and no drug
was detected in placental or fetal tissue or amniotic
fluid 30 min following IV injection, indicating com-
plete isolation ofthe uterus from the maternal blood
supply. Increasing amounts of drug were measured
in fetal and placental tissues and amniotic fluid fol-
lowing IP administration ofdrug at both 30 min and
4 hr. Transfer ofsignificant amounts ofdrugdirectly
to the fetoplacental unit can occur extraplacentally
following intraperitoneal drug treatment.
Toxic chemicals that cross the placenta may pro-
duce morbidity if administered after the stage of
organogenesis (second and third trimesters) or
malformations if administered during the first
trimester.
Mutagenic changes are distinguished from
teratogenic responses, in that the former is trans-
missable to future generations, whereas the later is
confined to a single generation. However certain
chemical-biological interactions may be common to
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FIGURE 4. Effect ofgestational age on diphenylhydantoin (DPH)
uptake in the human placenta. Each point represents the
mean of two to nine determinations ofuptake of 14C-DPH, 5
x 10-7M, measured after 30 or 60 min of incubation. ICF
denotes intracellular fluid.
both biological alterations, and it is on this
chemical-biological interaction, that I would like to
focus.
The term, "cytotoxic chemical," was initially
used to describe a number of chemically unrelated
agents which had in common the ability to inhibit
the growth oftumors. They act specifically on cells
in cycle. The most sensitive vegetable cells were
growing root tips and shoots of plants and ger-
minating seedlings. Bacteria are more sensitive in
the exponential growth phase than when growing
slowly in minimal media. Similar observations have
been made on a variety of systems ranging from
bacteria, yeast, higher plants and invertebrates to
vertebrates including primates. Acutely toxic doses
cause death by damaging proliferating tissues such
as bone marrow and intestinal mucosa. Survivors
may show symptoms of damage to epithelial sur-
faces to ovarian and testicular tissues and to any
system which contains cells in cycle and with a
short cycle time. Chronic administration of low
doses may produce cellular abnormalities and nu-
clear gigantism. Cytotoxic agents, because of their
broad spectrum of action, have been used not only
in treatment of cancer as immunosuppressants and
as insect chemosterilants, but also for studying
mechanisms of carcinogenesis, mutagenesis and
teratogenesis.
The mechanism by which chemicals cause cell
death is not clear, but effects have been ascribed to
some form ofunbalanced growth, RNA and protein
synthesis being out of phase with DNA synthesis.
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FIGURE 5. Concentrations of DPH plus metabolites in rat
placenta, fetus, and amnionic fluid after uterine ligation. Each
bar represents the mean ± SE of samples from 5-8 animals
treated IV with 50 mg/kg [14C] DPH (2.5ACi/kg) after ligation
of the uterus.
June 1978 89Table 2. Comparative cytotoxicity of two related dialkyltriazenes.
Dosage producing
50%,o fetal mortality,
mg/kg Teratogenicity Carcinogenicity
Day 10 Day 14 Day 10 Day 14 Day 10 Day 14
/~~~~CH3
N = N-N/ 10 100 0 +++ 0 +
N CH3
1-(3-pyridyl)3,3-dimethyltriazene
/ CH2CH3
= N - N'\ 60 170 +++ 0 ++ ++
CHXCH
1-(3-pyridyt)3,3-diethyltriazene
The phenomenon of unbalanced growth has been
described in detail for anumber ofcytotoxic agents.
The biological reactivity of cytotoxic agents is
similar but the teratogenic effects produced are de-
pendent on the gestational time of treatment. Di-
methyltriazene, for example, when injected into
pregnant rats on gestational day 10, has little
teratogenic action, but it is extremely effective if
administered on day 14 (Table 2). Conversely, a
closely related diethyltriazene is teratogenic at day
10 but not at day 14 (Table 2). There is also no
correlation between median lethal dosage,
teratogenicity and carcinogenicity. Thus, although a
compound may be classed as a cytotoxic agent, its
biological effects will vary from system to system.
Differences in toxicity or biological properties
between cytotoxic agents do not imply any major
differences in their mechanisms of action, but re-
flect differences in their physical-chemical proper-
ties. For example, there may be differences in
chemical or biological half-life, in tissue distribu-
tion, in metabolism and excretion of the chemical
and in the ability of target cells to repair damage.
There are several clear mechanisms of
teratogenic and mutagenic actions of cytotoxic
agents in biological organisms: alkylating agents,
electrophilic reactants, antimetabolites, intercalat-
ing agents, amino acid antagonists, spindle poisons,
and miscellaneous agents.
Cytotoxic agents destroy or alter dividing cells
and exert their characteristic biological properties
by several different mechanisms and vary as to site
of action in the cell.
Biological properties of alkylating agents have
been known for many years. Alkylating agents in
polar solvents are very reactive towards molecules
which have negative charges (nucleophiles) such as
ionized carboxylic and phosphoric acids and thiols,
or which have negative areas due to presence of
amine groups. These agents react with many
biological constituents including nucleic acids,
proteins, nucleotides, and amino acids. Some
alkylating agents have cytotoxic properties as
parent compounds. These include nitrogen mus-
tards, sulfonoxyalkanes, aziridines (ethylena-
mines), and oxiranes (epoxides). Their chemical
reactivity depends on the positively charged form
which reacts with negatively charged nucleophiles.
The teratogenicity and mutagenicity of these
chemicals depend on their electrophilic or posi-
tively charged character. Thus chemical reactivity
is dependent on electrophilic character.
,,CH2CH2Cl .CH2CH-
R-N > R N
CHCH 2CI -CH2 CH
NITROGEN MUSTARDS
zCH2OSO CH3 ICHi
R -> R
\ CH 0H20 CH3 \ CHi
SULPHONOXYALKANES
ZN-CH2CH2
3l R
\-N CH2CHi
AZIRIDINES
(ETHYLENEIMINES)
I-,0 R CH CH2
CH CH2
OXIRANES
(EPOXIDES)
6
H-CHi
R 0
CH-CH+
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are converted in vivo to electrophilic reactants. Al-
ready, a number of organic chemicals have been
identified as inherently electrophilic or converted in
v'iVo to electrophilic reactants that are carcinogenic.
Characteristically, these compounds are acutely
toxic if given as a single dose and carcinogenic on
chronic administration. For example, ingestion of
large amounts of aflatoxin contaminated foodstuffs
is known to cause acute hepatotoxicity, while in-
jection of small amounts can cause hepatocellular
carcinoma. Any carcinogen which acts by an inter-
mediate electrophilic reactant will have the general
properties ofcytotoxic agents and under the appro-
priate conditions will probably be a carcinogen.
This same hypothesis can be extended to include
electrophilic reactants as mutagens and teratogens.
Many variables are involved in determining
whether a chemical can be transformed in viVo to an
electrophilic reactant, and one of the most com-
prehensive studies has been carried out on 2-
acetylaminofluorene (4). This compound is a potent
liver carcinogen in a variety ofspecies, although the
guinea pig is resistant. There is a correlation be-
tween the binding of 2-acetylaminofluorene (AAF)
to nucleic acids and proteins and the degree of car-
cinogenicity. However, since AAF did not bind to
these macromolecules in vitro, it was clear that
some form of metabolic activation was taking place
in vivo. The scheme for activation of AAF is shown
in Eq. (1). AAF is metabolized in the liver to ring-
hydroxylated products, but a small amount of N-
hydroxylation also takes place. The N-hy-
droxylated metabolite is a more potent carcinogen,
but the ultimate carcinogen is the sulfate ester of
AAF which is rapidly rearranged to an electrophilic
reactant which covalently binds to macromolecules.
The guinea pig is not efficient in N-oxidation nor
does it possess significant sulphotransferase activ-
ity, thus explaining its resistance to AAF-induced
cancer.
The electrophilic AAF reactant attacks any cel-
lular molecule in its vicinity which has a negatively
charged region, a nucleophile. If the appropriate
level ofreaction takes place with the essential mac-
romolecule, then a cellular transformation will
occur. The degree and nature of the cellular lesion
will depend on a number of variables, the most im-
portant of which are: stage of embryo or fetal de-
velopment when chemical administered; dosage of
chemical, route of administration, and exposure
schedule; ability of chemical to pass placenta and
penetrate embryonic tissues; ability ofmaternal tis-
sues (especially liver) to detoxify or bioactivate
chemical; the biological and chemical half-life ofthe
material or its metabolite; capacity of embryonic
OH
,/H \ ;/ \NHCO CH3
II
/H \ / \NHCO-CH3
I
/ \ / N COCH3
OH
III
~1,
\ 'N COCH3
IV O-smo
0-
, < ~~N-CO-CH3
V
(1)
tissues to detoxify or bioactivate chemical; stage of
the cell cycle during the period when the drug is
present at a cytotoxic concentration; ability of the
damaged cells to repair or recover from the
cytotoxic lesion.
These variables explain why an agent may be
found to be highly teratogenic or mutagenic under
one set of experimental conditions and inactive in
another.
AAF is predominantly a liver carcinogen, pre-
sumably because the sulfate metabolite is such a
reactive chemical that it cannot travel far from its
site offormation in the liver. AAF is a teratogen. A
generalization can be made that a compound known
to be an electrophilic reactant must be considered to
be a potential teratogen. An important feature is the
chemical half-life which determines whether the
electrophilic reactant can travel from the site of
bioactivation to sensitive embryonic or fetal tissue.
If the intermediate metabolite is very reactive such
as the CC13 * radical formed from CCI4 it will be
unstable and react at the site of formation. Hence
CCI4 is very toxic to the adult liver and only a weak
teratogen, because the reactive chemical inter-
mediate is not transported to embryonic or fetal tis-
sue. Nitrosamines are similarly activated in the liver
to highly reactive carbonium ions which act at the
site offormation, the liver, and are not transported
to embryo or fetus to produce alterations. These
compounds are, however, mutagens when tested in
June 1978 91the Ames assay using liver microsomes as an en-
zyme source to bioactivate these materials to reac-
tive electrophiles.
Glutathione is an abundant and ubiquitous sulf-
hydryl compound in cells and appears to serve as an
electrophilic sink because of its nucleophilic prop-
erties. Thus it serves as a protective substance to
inhibit binding to essential macromolecules. Alter-
ations in cellular glutathione levels clearly alter the
toxicity of reactive electrophiles.
Bifunctional alkylating agents which are
teratogenic and mutagenic include busulphan (5, 6),
chlorambucil (7-10), cyclophosphamide (7, 11, 12),
METEPA (13), nitrogen mustard (5, 7, 14-16),
thio-TEPA (5, 17, 18), triethylenemelamine (7, 14,
19, 20), and uracil mustard (7). The proposed
mechanism of teratogenic activity of the bifunc-
tional alkylating agents is inter- or intrastrand
crosslinking of DNA as well as alkylation of other
essential macromolecules.
Electrophilic reactants which are teratogenic and
mutagenic are acetylaminofluorene (21), aflatoxin
(22), alkyltriazenes (23), aminoazobenzene (24),
benzanthracenes (25), benzpyrenes (26), carbon
tetrachloride (27, 28), cycasin (29), 1,2-
diethylhydrazine (30), ethionine (31, 32), methyl-
cholanthrene (33, 34), nitrosourea (35-37), pyrol-
lizidine alkaloids (38). These cytotoxic agents re-
quire metabolism or bioactivation. Liver micro-
somes most frequently produce a variety of elec-
trophilic reactants which, like the alkylating agents,
covalently bind to macromolecules. Metabolism or
bioactivation may also be extramicrosomal or by
gut bacteria. Some cytotoxic agents may also break
down spontaneously to chemically reactive inter-
mediates.
Antimetabolites which are teratogenic and
mutagenic include aminopterin (38-42), azaguanine
(43), azathioprine (44), azauracils (7, 28, 45-48),
cytosine arabinoside (7, 49-51), diaminopurine (7,
19), halogenated pyrimidines (7, 40, 52, 53), mer-
captopurine (7, 28, 54, 55), methotrexate (29, 56,
57), primethamine (58-60), and thioguanine (7, 17).
These antimetabolites inhibit pathways ofpurine or
pyrimidine biosynthesis and formation of
thymidylic acid. The mechanism for inhibition of
nucleic acid replication is by incorporation into
nucleic acids as base analogs and subsequent inhi-
bition of replication.
Intercalating agents which are teratogenic and
mutagenic include acriflavin (61), actinomycin D
(62-66), chloroquine (67-69), daunomycin (7),
quinacrine (70), and mithramycin (7). Intercalating
agents insert between base pairs of DNA and inter-
fere with transcription and replication.
Amino acid antagonists which are teratogenic and
mutagenic include asparaginase (71), azaserine
(72-74), DON (7, 75), p-fluorophenylalanine (43),
hadacidin (75, 77), and mimosine (78). Amino acid
antagonists inhibit protein and nucleic acid syn-
thesis by interfering with specific amino acids re-
quired for protein or nucleic acid synthesis. Specific
interference with asparagine, aspartic acid, gluta-
mine, methionine, phenylalanine, and tyrosine utili-
zation has been reported.
Spindle poisons which are teratogenic and
mutagenic include: colchicine (28), griseofulvin
(79), podophyllotoxin (7, 80, 81), vinblastine (31,
82-84), and vincristine (31, 82-84). Spindle poisons
condense with microtubular protein and interfere
with formation ofcellular organelles and the spindle
apparatus.
Miscellaneous cytotoxins which are teratogenic
and mutagenic include caffeine (85), formaldehyde
(86), hydroxyurea (10, 87-89), procarbazine (7), and
urethane (90). These agents covalently bind with
DNA and inhibit DNA synthesis and repair.
Alkylating agents are effective for suppressing
various types oftumor growth. To be effective anti-
cancer agents they must have an optimal level of
chemical reactivity (91). Alkylating agents in polar
solvents are reactive towards molecules which have
negative charges (nucleophiles) such as ionized car-
boxylic and phosphoric acids and thiols, or which
have negative areas due to presence of amine
groups. Alkylating agents react with many biologi-
cal constituents including nucleic acids, proteins,
nucleotides and amino acids. Nitrogen mustards,
ethyleneimines (aziridines), sulfonoxy-alkanes, and
epoxides (oxiranes) are alkylating agents possessing
cytotoxic properties. The chemical reactivity ofthe
alkylating agents results from formation of a posi-
tively charged species which subsequently reacts
with negatively charged molecules. This reaction
inactivates essential macromolecules necessary for
cellular multiplication, proliferation and growth.
This interaction is responsible for anticancer activ-
ity. Teratogenicity also depends on the chemical
reactivity of the alkylating agent. Alkylating agents
can kill dividing cells at any stage of the cell cycle.
Defects found and their severity are dependent on
the day of gestation on which the compounds are
administered (11). Some alkylating agents must be
biotransformed to chemically reactive species to be
teratogenic. Factors which influence metabolism,
e.g., stimulation or inhibition alter the teratogenic
properties of the compound. Cyclophosphamide,
for example, requires metabolic activation (92), and
any factor which influences this activation will af-
fect the teratogenicity of this compound. Similarly,
mitomycin C probably requires activation by initial
reduction of its guinone. The ability of embryonic
Environmental Health Perspectivestissues to reduce mitomycin may be the main factor
which determines its teratogenicity, since the active
metabolite probably has a very short half-life and
would not reach the embryo if it were generated
only in maternal liver.
Alkylating agents react nonspecifically with a va-
riety of cellular macromolecules. They all share a
common mechanism ofcytotoxicity. Theirchemical
reactivity is a result of inherent electrophilicity ac-
quired by dissolution in polar solvents or metabolic
activation. This physical characteristic imposes a
chemical reactivity that stimulates an attraction for
nucleophiles. A nucleophile is able to share or con-
tribute an electron with subsequent covalent bind-
ing of the two reactants. This covalent bonding ef-
fectively biologically inactivates target mac-
romolecules. At a molecular level this binding can
be to cell membranes, nucleoproteins, glycolytic
enzymes, DNA, RNA, cyclic AMP, etc. This
nonspecific binding results in impairment ofcellular
proliferation and growth. During embryonic de-
velopment impairment of cellular function is espe-
cially critical to future development of organ com-
ponents and systems. Covalent binding of the al-
kylating agents to essential macromolecules dis-
rupts cellular proliferation and growth and depend-
ing on the stage of development disrupts normal
development resulting in malformed or abnormal
offspring. Alkylating agents may also damage DNA
producing functional changes which lead to malig-
nant change or some other form of mutation.
Many synthetic and natural carcinogens are con-
verted in vivo to alkylating agents or some analo-
gous form of electrophilic reactant. These com-
pounds are acutely toxic at high doses and car-
cinogenic on chronic administration. Ingestion of
large amounts of aflatoxin contaminated foodstuffs
is known to cause acute hepatotoxicity, while in-
jection of small amounts can cause hepatocellular
carcinoma in a wide range ofanimal species. A car-
cinogen acting by electrophilic intermediates will
have the general properties of cytotoxic agents. A
number ofcarcinogenic chemicals have been shown
to be potent teratogens.
One of the most studied biotransformations of a
chemical to an electrophilic reactant is that of 2-
acetylaminofluorene (AAF) (4) [Eq. (1)]. There is a
correlation between binding of AAF metabolites to
nucleic acids and proteins and carcinogenicity.
AAF (I) is metabolized in the liver mainly to ring
hydroxylated products (II), but a small amount ,f
N-hydroxylation (III) also takes place. The N-hy-
droxy intermediate is a more potent carcinogen than
AAF. However, neither the AAF or N-hydroxy
metabolite bind with cellular macromolecules. Sul-
fation of the N-hydroxy metabolite IV produces
the proximate carcinogen. The sulfate group forms
an excellent leaving group for spontaneous chemi-
cal rearrangement to form the reactive electrophilic
amidonium ion (V). Synthetic esters of III do co-
valently bind to cellular macromolecules. The elec-
trophilic reactant formed attacks any cellular
molecule in its vicinity which has a negatively
charged region (nucleophile). A critical level of
electrophilic reactant is necessary for cytotoxicity.
The level ofreactant formed will depend on the bal-
ance between bioactivation and detoxification.
AAF is a liver carcinogen because the active sul-
fate is such a reactive chemical that it cannot travel
far from its site of formation in the liver. AAF also
induces tumors in mammary glands, epithelium of
small intestine, and in sebaceous ear duct glands,
which implies these tissues also activate AAF or
that another unidentified metabolite is formed in the
liver which is stable enough to diffuse from the liver
and reach distant tissues. AAF produces skeletal
defects when administered to mice between gesta-
tional days 8 and 15 (21). Fetal liver does not
metabolize AAF since no hepatotoxicity was ob-
served, but some form of cytotoxic agent is being
produced by maternal tissues which reach the em-
bryo in active form.
Electrophilic reactants are highly carcinogenic as
well as teratogenic. Without exception, it has been
found that the active metabolite is an electrophilic
reactant (Table 3) (93). A compound known to be an
electrophilic reactant (for example, an alkylating
agent) must be considered a potential teratogen.
The chemical half-life of the reactant determines
whether it can travel from the site of injection to
sensitive embryonic tissues. Compounds with no
inherent reactivity to nucleophiles but biotrans-
formed to chemically reactive intermediates must
be considered potential teratogens. Very reactive
intermediates, such as the CC13 * radical, formed
from carbon tetrachloride will be unstable and react
at the site offormation. Carbon tetrachloride is very
toxic to adult liver where it is generated but not very
toxic in newborn rats whose metabolic enzymes are
not fully developed (94). This is in agreement wifh
the weak teratogenic action of carbon tetrachloride
which caused no congenital defects in offspring of
rats (27). Aflatoxins are metabolized, by the liver to
an epoxide which has a very short half-life and acts
mainly on the liver (95). However, despite the short
half-life of the metabolite, the aflatoxins are
teratogenic (22).
Nitrosamines are similarly activated in the liver
to reactive electrophilic carbonium ions which are
hepatotoxic. Nitrosamines are not powerful induc-
ers of transplacental cancer because the active
metabolite is too unstable to reach the fetus. The
June 1978 93fetus is unable to activate the nitrosamines until
shortly before birth (93). Chemically related nitro-
soureas are teratogenic because they are stable
enough to cross the placenta and be demonstrable in
the embryo (96). Monoalkyltriazenes which are
formed from dialkyltriazenes by metabolic de-
methylation are chemically stable having chemical
half-lives of the order of ten minutes. The chemical
stability of the monoalkyltriazenes allows time for
diffusion from maternal liver and penetration of
embryonic tissue resulting in teratogenicity (23).
Removal of the sugar residue from cycasin in vivo
produces an electrophilic reactant that is stable
enough to be carcinogenic and teratogenic. Me-
tabolic activation of the cycasin is dependent on
species, age and condition of the test species, thus
teratogenicity of the compound is widely variable.
Ethionine is bioactivated in the liver to S-adeno-
syl-L-ethionine which can ethylate macromolecules
causing cell abnormalities. Adenosylethionine is
chemically stable and can penetrate to embryonic
tissues and cause teratogenic effects. Aminoazo-
benzenes are teratogenic (24). These chemicals are
bioactivated to amidonium ions by N-hydroxylation
and subsequent esterification in a manner analogous
to that previously described for acetylamino-
fluorene. Polycyclic hydrocarbons are metaboli-
cally converted to epoxides which are very reactive
electrophiles. This class of chemicals is highly
teratogenic and mutagenic. Not all the hy-
drocarbons are alike in their teratogenic properties.
Benzpyrene is not an effective teratogen (97). How-
ever, 7,12-dimethylbenzanthracene produces a high
incidence of defects (25). Pyrolizidine alkaloids
have a similar structure as mitomycin C and both
are probably active only after conversion to a pyr-
role analog.
Glutathione is the most abundant and ubiquitous
sulfydryl compound in cells and appears to serve as
an electrophilic sink by nature of its nucleophilic
properties. Thus glutathione serves as an elec-
trophile scavenger to inhibit binding ofbioactivated
chemicals to essential macromolecules. Alterations
in cellular glutathione levels clearly alters the tox-
icity of reactive electrophiles. Decreasing cellular
glutathione levels enhances the toxicity of bioac-
tivated materials.
Diphenylhydantoin (DPH) is bioactivated to a
teratogen. DPH binds covalently to both maternal
and fetal tissues; 132 pg of DPH bound to maternal
liver and 225 pg of DPH bound to fetal tissue 4 hr
following a dosage of 50 mg/kg DPH administered
IP. Covalent binding was measured as previously
described (98).
Several metabolites of DPH have been identified
in vivo. Conclusive evidence for the presence of
Table 3. Chemical structure of teratogen and active metabolite.
Teratogen Active Metabolite
/77-<4' A NH*CO*CH3 > N*CO*CH3
Acetv1aminnflurene
0 0
0
1
O 0 OCH3
Aflatoxin B1
f.
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Glu OCH-N=N CH
11
0
Cycasin
,/<\N=N N(CH3)2
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CH3 --NO
CH3/
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0 0
0
o - OCH3
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HO
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Environmental Health Perspectivesdiphenylhydantoic acid and a-aminodiphenylacetic
acidin vivo following the administration ofDPH, by
using melting point, elemental analysis, and chro-
matography, was provided by Maynert (99) in iden-
tifying these products in the urine ofdogs, rats, and
people. In addition to these two degradative prod-
ucts Butler (100) demonstrated that one of the
phenyl groups in DPH is hydroxylated in the para
position. He also found that unchanged DPH is ex-
creted in very small amounts if at all in urine and
concluded that DPH is biotransformed by dogs and
people to 5-p-(hydroxyphenyl)-5-phenylhydantoin
(HPPH), conjugated, and excreted. Maynert (99)
also found the major urinary product to be HPPH.
Chang et al. (101) identified 5-(3,4-dihydroxy-1,5-
cyclohexadien-l-yl)-5-phenylhydantoin as a
metabolite of DPH in rat and monkey urine. Atkin-
son et al. (102) identified 5-m-hydroxyphenyl-5-
phenylhydantoin in conjugate form in the urine of
dogs and patients treated with DPH. HPPH is prob-
ably the major hydroxylated metabolite of DPH. A
proposed schematic for the metabolism of DPH is
shown in Figure 6. DPH is converted to a dihy-
drodiol in mouse, rat, dog, and man (103). The
existence of a dihydrodiol is evidence for an inter-
mediate epoxide. The DPH epoxide may be in
equilibrium with the chemically stable oxepin.
DPH-dihydrodiol may be further converted to
catechols and conjugates.
The metabolism of polycyclic aromatic hy-
drocarbons by the hepatic mixed function oxidase
system has been extensively studied. It has been
demonstrated that the arene oxide and dihydrodiol
derived from benzypyrene are very reactive
electrophiles which bind in vitro and in vivo to
biological macromolecules. Covalent binding of
these macromolecules is responsible for the tissue
damage observed on exposure to these metabolites
or the parent hydrocarbon. Comparatively little
work has been done to identify the chemical species
responsible for tissue damage on treatment with
monocyclic aromatic derivatives such as DPH. The
dihydrodiol and other hydroxylated metabolites of
DPH have been isolated suggesting an intermediate
arene oxide.
Pretreatment of pregnant mice with diethyl
maleate DEM (a depletor ofglutathione) enhanced
the teratogenicity of DPH. DPH at a dosage of 50
mg/kg administered orally produced 2% incidence
of cleft palate (Table 4). Pretreatment of pregnant
mice with DEM increased the DPH-induced inci-
dence of cleft palate to 24% (Table 4). Similarly,
DEM and trichloropropane (TCP), an epoxide hy-
drase inhibitor, increase DPH-induced fetal resorp-
tions (Fig. 7). DPH, 50 mg/kg administered orally,
induced about 10%o incidence of fetal resorptions.
DIPHENYLGLYCINE
OH 9 9 , Q
C -COON 4 C C=o C - -C=O --- P-HPPH glucuronide
N IN IHN p-HPPH sulfote?
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FIGURE 6. Proposed biotransformation of diphenylhydantoin in
vivo to an electrophilic reactant.
DEM increased by 4-fold the incidence of DPH-
induced fetal resorptions. TCP also significantly in-
creased the incidence of fetal resorptions. SKF
(,8-diethyl-aminoethyldiphenyl propylacetate), an
inhibitor of microsomal metabolism also enhanced
DPH-induced fetal resorptions. DEM also in-
creased the covalent binding ofDPH to fetal tissues
(Table 5). DEM pretreatment doubled the binding of
DPH to fetal tissue. DPH binding was increased
from 250 pg to 570 pg/mg of fetal tissue by DEM
pretreatment. A reactive metabolite of DPH, an
epoxide, may be responsible for its teratogenicity.
Alkylating agents induce mutations, chromo-
somal aberrations, and cancer (104). Rubratoxin B, a
metabolite of Penicillium rubrum, is a mycotoxin
that produces a midzonal hepatic necrosis and nep-
hrosis (105). A substituted analog of byssochlamic
acid, in which the ethyl group is replaced by a 6-
a,,3-unsaturated lactone, rubratoxin B is a potential
alkylating agent. Chronic treatment with rubratoxin
B produced both hepatic and renal histopathological
changes but no tumorigenic activity was noted (105,
106). However, Umeda et al. (107) reported that
rubratoxin B increased the mitotic rate of HeLa
June 1978 95Table 4. Effect of diethyl maleate pretreatment on
diphenylhydantoin (DPH)-induced cleft palates.a
Incidence of
Treatment cleft palate, %
DPH 2 0.9
DPH + DEM 24 3
a Diethyl maleate (DEM) pretreatment, 150 mg/kg, IP, 30 min
prior to DPH, 50 mg/kg, PO. Values are the mean percent inci-
dence ± SE. Pregnant animals were treated on gestational days
12, 13, and 14.
TableS. Effect ofdiethyl maleate (DEM) pretreatment on diphenyl
hydantoin (DPH) binding to fetal tlssue.a
Fetal DPH binding
Treatment pg DPH/mg tissue
DPH 250 90
DPH + DEM 570 ± 50
a Diethyl maleate pretreatment, 150 mg/kg, IP, 30 min prior to
DPH, 50 mg/kg, PO. Values are the mean ± SE. Pregnant ani-
mals were treated with DPH (20,Ci/kg) on gestational day 14
and sacrificed 4 hr following treatment.
DPH
DPH
SKF
DPH
DEM
DPH
TCP
*
10 20 30 40 50 60 70
RESORPTIONS (% ± S. E.)
FIGURE 7. Effect of SKF-525A (SKF), diethyl maleate (DEM),
and 1,2-epoxy-3,3,3-trichloropropane (TCP) pretreatment on
diphenylhydantoin (DPH)-induced fetal resorption rates.
DPH, 50 mg/kg PO, was administered on gestational day 12,
13, and 14; DEM, 150 mg/kg IP, was administered 30 min
prior to each DPH treatment; SKF, 40 mg/kg IP, was ad-
ministered I hr prior to each DPH treatment; TCP, 150 mg/kg
SC, was administered I hr prior to each DPH treatment.
cells and produced chromosomal damage.
Aflatoxin, a toxic metabolite of Actinomyces
flavus is a known carcinogen and mutagen and also
contains an unsaturated lactone ring. The mech-
anism of aflatoxin toxicity is probably related to
formation of an epoxide of the dihydrofuran ring
which binds to nucleophilic groups of nucleic acids
(108).
To assess evidence for dominant lethal muta-
tions, male mice were treated with rubratoxin for 5
days (109).
During the first 4 weeks of mating, rubratoxin B
induced a significant dose-related increase in the
number of pregnant females having early fetal
deaths. Rubratoxin B, 1.5 mg/kg, produced early
fetal deaths in 100% ofthe females during the first 3
weeks of mating. Frequency of females with early
fetal deaths returned to control levels during the
fifth week of mating. A dose-response relationship
was observed.
Rubratoxin B induced a significant increase in the
number of early fetal deaths per pregnancy during
the first, second, third, and fourth weeks ofmating.
Again, a dose-response relationship was observed.
Rubratoxin B, 1.5 mg/kg, increased the number of
early fetal deaths 300 to 400%o above controls at
these intervals.
Hydrogenation of rubratoxin saturates the a,,4-
unsaturated lactone ring and inhibits the bioactiva-
tion of this ring to a reactive electrophilic inter-
mediate.
Hydrogenated rubratoxin did not increase the
frequency offemales with early fetal deaths nor did
the hydrogenated rubratoxin increase the number of
early fetal deaths per pregnancy.
Embryotoxicity was observed in pregnant mice
administered rubratoxin B. Control resorption rate
was about 2%. Rubratoxin B administered on ges-
tational days 8, 9, and 10 or 12, 13, and 14 produced
a significantly higher resorption rate. Rubratoxin B,
0.5 mg/kg, killed 90%o of the fetuses when injected
on gestational days 8, 9, and 10, but only 22% ofthe
fetuses were killed when rubratoxin administration
was on gestational days 12, 13, and 14.
Hydrogenated rubratoxin (l0 mg/kg) did not in-
crease resorption rate when administered on gesta-
tional days 8,9, and 10 orongestational days 12, 13,
and 14 when compared to control. Similarly, it did
not alter the body weight of surviving fetuses when
administered at dosages greater than 20 times the
dosage of rubratoxin B.
Various anomalies were noted after single and
multiple-day treatment with rubratoxin B. Head,
eye, ear, and kidney anomalies were dominant fol-
lowing treatment on day 8 of gestation. Orofacial,
brain, lung, liver, and kidney anomalies were dom-
inant following treatment on day 12, 13, or 14 of
gestation. No treatment-associated defects were
observed following administration of hydrogenated
Environmental Health Perspectives 96rubratoxin on gestational days 8, 9, and 10 or days
12, 13, and 14 at a dosage ofeither 1.0 or 10 mg/kg.
Compounds containing a lactone structure pos-
sess a wide range ofpharmacological and cytotoxic
properties (110-112). Since many lactones are elec-
trophilic reacting, the biological activity of these
compounds has been attributed to their action as
alkylating agents (113), and alkylation of nucleic
acids, particularly the N-7 position ofguanine, has
been suggested as the site of action for many lac-
tones in susceptible cells (114). Previous studies
have demonstrated that rubratoxin B is a potent
toxin, but, unlike aflatoxin and other lactone-
containing compounds, rubratoxin B did not pro-
duce observable chromosomal damage. However,
our studies demonstrated that rubratoxin B, pos-
sessing an a,43-unsaturated lactone ring, is a potent
mutagen and teratogen.
Rubratoxin B is biologically more reactive than
its hydrogenated analog. Hydrogenation of the lac-
tone ring decreases the electrophilic properties of
this moiety and also the possible oxidation or
bioactivation of this moiety to a reactive inter-
mediate with strong electrophilic characteristics.
The mechanism of rubratoxin-induced toxicity to
the reproductive process is probably electrophilic
attack by the lactone moiety to bind to essential
macromolecules irreversibly and inhibit cellular
proliferation.
Antimetabolites are antitumor agents and are di-
vided into purine and pyrimidine antagonists and
antifolates. Amino acid antagonists may also be
considered antimetabolites and alter cellulargrowth
and development.
The 6-substituted purines such as azathioprine,
mercaptopurine, thioguanine, and chloropurine and
heterocyclic ring analogs such as 8-azaguanine are
teratogenic and mutagenic. These agents prevent
the formation of the nucleic acid bases, adenylic
and guanylic acids from inosinic acid. The base
analogs operate at the pathways at the nucleotide
di- and triphosphate levels. Thus, the base analogs
are bioactivated to the appropriate ribotide or
deoxyribotide before they act as antagonists. The
level of the activating enzyme in a cell will be one
factor determining its sensitivity to the antimetabo-
lite. The teratogenic and mutagenic antimetabolites
are reversible antagonists acting specifically at one
stage of the cell cycle, usually the DNA-synthetic
phase. The antimetabolite effects are dose
schedule-dependent, unlike the electrophilic reac-
tants which react irreversibly at all stages ofthe cell
cycle. A single high dose ofantimetabolite may not
be effective, while a smaller dose administered over
a period oftime may be much more effective. To be
effective, the antimetabolite must be present for the
time it takes all target cells to enter and pass
through the sensitive phase ofthe cell cycle. Thus, a
single dose of an antimetabolite may not be effec-
tive because only a portion of the cells are exposed
to the drug when they are in a sensitive phase.
However, a small minimum effective dose of the
compound administered for at least one cell cycle
may be effective. Fetal tissues contain cells growing
almost synchronously and of a very short cycle
time. Therefore, a single dose of an antimetabolite
given at the critical time of development can be
teratogenic (7, 17, 43, 44, 55). Antipyrimidines must
also be converted to nucleotides before having
teratogenic or mutagenic activity. They act on
specific phases of the cell cycle and are dose
schedule dependent. The antimetabolites inhibit
various stages of pyrimidine biosynthesis, particu-
larly the formation of thymidylic acid from
deoxyuridylic acid. Antifolates inhibit the produc-
tion oftetrahydrofolate, which eventually results in
inhibition of nucleic acid and protein synthesis.
Three antifolates which have been shown to be
teratogenic are aminopterin, methotrexate, and
pyrimethamine.
Intercalating agents form very stable complexes
with DNA. Unlike alkylating agent-DNA com-
plexes, they do not form covalent linkages, since
these compounds may be dissociated in unaltered
form by modification ofthe ionic environment. The
effect of complexing is to modify the configuration
of the DNA double helix and to interfere with its
template activity. Planar molecules containing a
number of conjugated aromatic rings are most effi-
cient in binding to DNA. Intercalating agents react
with the double helix DNA to cause unwinding and
insertion of single molecules between stacked base
pairs. Intercalating agents are teratogenic and the
effects produced are dependent on gestational day
of administration (64). These agents are also
mutagenic by a similar mechanism.
Amino acid antagonists inhibit protein synthesis.
A few amino acid antagonists are teratogenic (43,
76-78, 115). Azaserine and DON are two glutamine
antagonists which are teratogenic (7, 72-75). As-
paraginase enzymes hydrolyze circulating as-
paragine to aspartic acid. Rapidly growing em-
bryonic tissues are not able to synthesize sufficient
asparagine from aspartic acid and asparaginase at
low doses is teratogenic (71). Amino acid an-
tagonists are similarly teratogenic.
Some materials are able to inhibit growth by ar-
resting cells at mitosis. They inhibit cells in meta-
phase by interfering with formation of the mitotic
spindle apparatus. Spindle poisons are teratogenic
and mutagenic (31, 83). They condense microtubu-
lar protein and prevent formation of essential cell
June 1978 97structures.
Other cytotoxic agents which are teratogenic are
hydroxyurea and urethane which inhibit nucleic
acid synthesis by preventing reduction of ribonu-
cleotides and reacting directly with nucleic acid
bases. Procarbazine breaks down to a number of
products which covalently bind with DNA. For-
maldehyde is mutagenic and teratogenic and acts by
reacting with amino groups ofthe purines of nucleic
acids.
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